Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

951 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-07-31

Study Completion Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A cholesterol/lipid profile screening project of high risk patients with hyperlipidaemia (secondary prevention) who already receive cholesterol-lowering therapy. Lipid profile and rate of patients who are treated to target (which is \<100mg/dl for patients with high risk and \<70mg/dl for patients at very high risk) are screened (office-based specialists). The doctors therapy decisions after the screening and possible reasons for these decisions will be documented. Our aim is to evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and to underline the importance of treating patients to their cholesterol targets.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets

NCT00536796

Hyperlipidemias Atherosclerosis Coronary Heart Disease +3 more

COMPLETED

A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels

NCT00327691

Cardiovascular Disease Cerebrovascular Accident Coronary Heart Disease

COMPLETED PHASE4

Pleiotropic Effects of Atorvastatin in High Cardiovascular Risk Patients

NCT01013103

Coronary Artery Disease HMG-CoA Reductase Inhibitor Toxicity Atherosclerosis +2 more

COMPLETED PHASE4

Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)

NCT00723723

Coronary Heart Disease Hypercholesterolemia Hyperlipidemia

COMPLETED

Drug Interaction Study - Assess Pharmacokinetics of Both AZD5672 and Atorvastatin

NCT00722956

Healthy Volunteers Pharmacokinetics

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperlipidemias Atherosclerosis Coronary Heart Disease Carotid Stenosis Peripheral Vascular Diseases Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Secondary prevention patients with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PVD, etc.) and/or diabetes who already receive cholesterol-lowering therapy